Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor
A phase 3 trial testing OSE2101 in non-small-cell lung cancer, now recruiting.
Overview
Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor is a phase 3 interventional study registered as NCT06472245, led by OSE Immunotherapeutics with Exystat and GeneDx, and recruiting when checked on 2026-09-11. Official title: A Randomised, Open-label, Phase 3 Trial Comparing the Efficacy and Safety of OSE2101 Versus Docetaxel in HLA-A2 Positive Patients With Metastatic Non-Small Cell Lung Cancer (NSCLC) With Secondary Resistance to Immune Checkpoint Inhibitor. Planned enrolment is 363 participants (estimated). The study started in 2024-12-03 and primary completion is expected in 2027-12-15. No results have been posted on ClinicalTrials.gov.
Similar pages
not linked directly; found by shared links- TrialSSGJ-707 in Advanced Non-Small Cell Lung Cancer
Shares Non-small-cell lung cancer and the tag ctgov-ingest.
- TrialSymbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Shares Non-small-cell lung cancer and the tag ctgov-ingest.
- TrialSymbiotic-Lung-04: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Extensive-Stage Small Cell Lung Cancer
Shares Non-small-cell lung cancer and the tag ctgov-ingest.
- TrialA Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)
Shares Non-small-cell lung cancer and the tag ctgov-ingest.
- TrialA Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)
Shares Non-small-cell lung cancer and the tag ctgov-ingest.
- TrialMK-3475A±Calderasib (MK-1084) in Completely Resected Stage IIA-IIIB (N2) KRAS G12Cm NSCLC (MK-1084-013)
Shares Non-small-cell lung cancer and the tag ctgov-ingest.
- TrialA Clinical Trial of Calderasib (MK-1084) and Durvalumab in People With Non-Small Cell Lung Cancer (MK-1084-015/KANDLELIT-015)
Shares Non-small-cell lung cancer and the tag ctgov-ingest.
- TrialA Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC
Shares Non-small-cell lung cancer and the tag ctgov-ingest.